CREXONT
CREXONT is a combination of carbidopa and levodopa indicated for the treatment of Parkinson's disease in adult patients. The medication is also approved for the treatment of post-encephalitic parkinsonism and parkinsonism resulting from carbon monoxide or manganese intoxication. By combining an aromatic amino acid with a decarboxylation inhibitor, the drug provides a therapeutic approach to managing the symptoms associated with these various forms of parkinsonism.
How CREXONT Works
Levodopa serves as a metabolic precursor to dopamine that crosses the blood-brain barrier to be converted into dopamine within the brain. Because levodopa is typically converted to dopamine in peripheral tissues before reaching the central nervous system, carbidopa is included to inhibit this peripheral decarboxylation. By blocking this extracerebral conversion, carbidopa increases the amount of unchanged levodopa available for transport to the brain. This mechanism ensures that the precursor reaches the brain to be converted into the neurotransmitter dopamine.
Details
- Status
- Prescription
- First Approved
- 2024-08-07
- Routes
- ORAL
- Dosage Forms
- CAPSULE, EXTENDED RELEASE
CREXONT Approval History
What CREXONT Treats
3 indicationsCREXONT is approved for 3 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Parkinson's Disease
- Post-Encephalitic Parkinsonism
- Parkinsonism
Drugs Similar to CREXONT
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CREXONT FDA Label Details
ProIndications & Usage
FDA Label (PDF)CREXONT is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults. CREXONT is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults.
CREXONT Patents & Exclusivity
Patents (976 active)
Exclusivity
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.